Business
Avalo to Present at Two Upcoming Conferences
WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company
About this update from Avalo Therapeutics, Inc.
[{"type":"text","content":"WAYNE, Pa. and ROCKVILLE, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases announced today that members of its senior management team will present at two upcoming conferences. Stifel 2021 Virtual Healthcare ConferenceDate: Wednesday, November 17, 2021Time: 4:00 PM ET Jefferies 2021 London Healthcare ConferenceDates: November 16-18, 2021A pre-recorded presentation will be available on-demand starting on Thursday, November 18, 2021 at 8:00 AM GMT. A live webcast of the presentation at the Stifel 2021 Virtual Healthcare Conference and pre-recorded presentation at the Jefferies 2021 London Healthcare Conference can be accessed under the \"News/Events\" page in the Investors section of the Company's website at www.avalotherapeutics.com. A replay of the events will also be available on the Company’s website. About Avalo Therapeutics Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The Company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success. Forward-Looking Statements This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Avalo’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Avalo’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,”...